References
  1. Akazawa, Y., & Nakao, K. (2018). To die or not to die: death signaling in nonalcoholic fatty liver disease. Journal of Gastroenterology, 53, 893 - 906. https://doi.org/10.1007/s00535-018-1451-5.
  2. Bq, S. (2021). Use of Silimarin in the Treatment of Non-Alcoholic Fatty Liver Disease (Nafld). Academic Journal of Gastroenterology & Hepatology. https://doi.org/10.33552/ajgh.2021.03.000552.
  3. Starley, B., Calcagno, C., & Harrison, S. (2010). Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology, 51. https://doi.org/10.1002/hep.23594.
  4. Kim, K., & Lee, M. (2018). Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. Frontiers in Endocrinology, 9. https://doi.org/10.3389/fendo.2018.00485.
  5. Sumida, Y., & Yoneda, M. (2017). Current and future pharmacological therapies for NAFLD/NASH. Journal of Gastroenterology, 53, 362 - 376. https://doi.org/10.1007/s00535-017-1415-1.
  6. LI, Huating et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal of Hepatology, v. 53, n. 5, p. 934-940, nov. 2010. Disponível em: https://doi.org/10.1016/j.jhep.2010.05.018
  7. XU, P. et al. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways. Toxicology and applied pharmacology, v. 290, p. 43–53, 2016.
  8. TILLMAN, E. J.; ROLPH, T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Frontiers in Endocrinology, v. 11, 14 dez. 2020.
  9. ANA RAIMUNDA DÂMASO et al. Effects of an interdisciplinary weight loss program on fibroblast growth factor 21 and inflammatory biomarkers in women with overweight and obesity. Archives of Endocrinology and Metabolism, 11 nov. 2021.
  10. Loomba, R., Sanyal, A. J., Nakajima, A., Neuschwander-Tetri, B. A., Goodman, Z. D., Harrison, S. A., Lawitz, E. J., Gunn, N., Imajo, K., Ravendhran, N., Akahane, T., Boone, B., Yamaguchi, M., Chatterjee, A., Tirucherai, G. S., Shevell, D. E., Du, S., Charles, E. D., & Abdelmalek, M. F. (2024). Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 22(1), 102–112.e9. https://doi.org/10.1016/j.cgh.2023.04.011
  11. Abdelmalek, M. F., Sanyal, A. J., Nakajima, A., Neuschwander-Tetri, B. A., Goodman, Z. D., Lawitz, E. J., Harrison, S. A., Jacobson, I. M., Imajo, K., Gunn, N., Halegoua-DeMarzio, D., Akahane, T., Boone, B., Yamaguchi, M., Chatterjee, A., Tirucherai, G. S., Shevell, D. E., Du, S., Charles, E. D., & Loomba, R. (2024). Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 22(1), 113–123.e9. https://doi.org/10.1016/j.cgh.2023.04.012
  12. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.
  13. Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:71.
  14. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
  15. Harrison, S. A., Ruane, P. J., Freilich, B. L., Neff, G., Patil, R., Behling, C. A., Hu, C., Fong, E., de Temple, B., Tillman, E. J., Rolph, T. P., Cheng, A., & Yale, K. (2021). Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nature medicine, 27(7), 1262–1271. https://doi.org/10.1038/s41591-021-01425-3
  16. Harrison, S. A., Ruane, P. J., Freilich, B., Neff, G., Patil, R., Behling, C., Hu, C., Shringarpure, R., de Temple, B., Fong, E., Tillman, E. J., Rolph, T., Cheng, A., & Yale, K. (2022). A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP reports : innovation in hepatology, 5(1), 100563. https://doi.org/10.1016/j.jhepr.2022.100563
  17. Harrison, S. A., Frias, J. P., Neff, G., Abrams, G. A., Lucas, K. J., Sanchez, W., Gogia, S., Sheikh, M. Y., Behling, C., Bedossa, P., Shao, L., Chan, D., Fong, E., de Temple, B., Shringarpure, R., Tillman, E. J., Rolph, T., Cheng, A., Yale, K., & HARMONY Study Group (2023). Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. The lancet. Gastroenterology & hepatology, 8(12), 1080–1093. https://doi.org/10.1016/S2468-1253(23)00272-8
  18. Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., Gottwald, M. D., Feng, S., Agollah, G. D., Hartsfield, C. L., Mansbach, H., Margalit, M., & Abdelmalek, M. F. (2023). Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. The New England journal of medicine, 389(11), 998–1008. https://doi.org/10.1056/NEJMoa2304286
  19. Loomba, R., Lawitz, E. J., Frias, J. P., Ortiz-Lasanta, G., Johansson, L., Franey, B. B., Morrow, L., Rosenstock, M., Hartsfield, C. L., Chen, C. Y., Tseng, L., Charlton, R. W., Mansbach, H., & Margalit, M. (2023). Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. The lancet. Gastroenterology & hepatology, 8(2), 120–132. https://doi.org/10.1016/S2468-1253(22)00347-8
  20. Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., Luo, Y., & Christian, R. (2019). Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet (London, England), 392(10165), 2705–2717. https://doi.org/10.1016/S0140-6736(18)31785-9
  21. Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord 2022;22:63.
  22. Machado MV, Diehl AM. Pathogenesis of Nonalcoholic Steatohepatitis. Gastroenterology 2016; 150:1769.
  23. Lee Y, Doumouras AG, Yu J, et al. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019; 17:1040.
  24. Shroff H, VanWagner LB. Cardiovascular disease in nonalcoholic steatohepatitis: screening and management. Curr Hepatol Rep 2020; 19: 315–26.
  25. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol 2015; 13:2062.
  26. Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 2023; 401:1786.
  27. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146: 726–35.
  28. Romero-Gómez M, Lawitz E, Shankar RR, et al. A phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease. J Hepatol 2023; published online June 22. https://doi.org/10.1016/ j.jhep.2023.05.013.
  29. Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterol 2018;155:1140–1153.
  30. Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 2020;73:26–39.
  31. Sanyal AJ, Harrison SA, Ratziu V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 2019;70:1913–1927.
  32. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022; 28:528.
  33. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64:1388.
  34. Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med 2016; 165:305.
  35. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017; 64:319.
  36. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77:1797.
  37. Cusi K. Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. Hepatology 2019; 69:2318.
  38. Ferguson, D., & Finck, B. N. (2021). Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature reviews. Endocrinology, 17(8), 484–495.
  39. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021; 384:1113.
  40. Rader, D. J., Maratos-Flier, E., Nguyen, A., Hom, D., Ferriere, M., Li, Y., Kompa, J., Martic, M., Hinder, M., Basson, C. T., Yowe, D., Diener, J., Goldfine, A. B., & CLLF580X2102 Study Team (2022). LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia.
  41. Bhatt, D. L., Bays, H. E., Miller, M., Cain, J. E., 3rd, Wasilewska, K., Andrawis, N. S., Parli, T., Feng, S., Sterling, L., Tseng, L., Hartsfield, C. L., Agollah, G. D., Mansbach, H., Kastelein, J. J. P., & ENTRIGUE Principal Investigators (2023). The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nature medicine , 29 (7), 1782–1792.
  42. Huang, Z., Xu, A., & Cheung, B. M. Y. (2017). The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension. Current hypertension reports, 19(4), 28.
  43. Zarei, M., Pizarro-Delgado, J., Barroso, E., Palomer, X., & Vázquez-Carrera, M. (2020). Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. Trends in pharmacological sciences , 41 (3), 199–208.
  44. Bhatt, D. L., Bays, H. E., Miller, M., Cain, J. E., 3rd, Wasilewska, K., Andrawis, N. S., Parli, T., Feng, S., Sterling, L., Tseng, L., Hartsfield, C. L., Agollah, G. D., Mansbach, H., Kastelein, J. J. P., & ENTRIGUE Principal Investigators (2023). The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nature medicine, 29(7), 1782–1792.